OSE-127

April 23, 2019April 24, 2019

OSE-127 Therapy Candidate Prevents Gut Inflammation by Immune Cells, Study Reports

News

OSE Immunotherapeutics’ therapeutic candidate OSE-127 for chronic inflammatory bowel disease (IBD) showed anti-inflammatory activity in a study performed in mice and patients’ samples. The study, “IL-7 receptor influences anti-TNF responsiveness ... Read more

May 14, 2018May 14, 2018

OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD

News

OSE Immunotherapeutics presented new preclinical results on its investigational therapy candidate OSE-127, further validating its potential for the treatment of inflammatory bowel diseases (IBD). Results were presented in an abstract titled, ... Read more

January 3, 2018

Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says

News

A study that OSE Immunotherapeutics conducted on the role that a protein receptor plays in bowel disease supports its development of a treatment that blocks the receptor, the company reports. It designed OSE-127 ... Read more

June 19, 2017June 19, 2017

OSE Immunotherapeutics Says its IBD Candidate OSE-127 Could Help Treatment-resistant Patients

News

OSE Immunotherapeutics presented promising data from preclinical experiments of its investigational treatment OSE-127 (Effi-7) for inflammatory bowel disease (IBD) at FOCIS 2017, the Federation of Clinical Immunology Societies, held June 14-17 in ... Read more